# Vaxart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaxart

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.vaxart.com
- Total disclosed funding: $39M
- Latest round: Series C (Aug 5, 2013)
- Investors on record: 5

## About

Vaxart, Inc. is a biotechnology company focused on developing oral recombinant vaccines aimed at providing immunity against various viral diseases. Their innovative platform presents a unique approach to vaccination beyond traditional methods.Vaxart, Inc. specializes in the development of oral vaccines. Founded in 2004, the company is headquartered in San Francisco, US. In February 2018, Vaxart completed a reverse merger with Aviragen Therapeutics Inc., resulting in all VC investors exiting their stake. The firm has engaged in 8 deals, with its most recent funding round in July 2020 led by Care Capital, raising USD 18.40 mn, bringing the total amount raised to USD 18.40 mn. Andrei Floroiu is the current CEO.Vaxart focuses on oral recombinant pill vaccines that aim to provide mucosal and systemic immunity against viral diseases. Their technology creates vaccines targeting COVID-19, norovirus, influenza, and human papillomavirus (HPV). These products are designed for diverse markets, especially areas with high viral infection rates, and are intended for healthcare providers, public health organizations, and the general population.In the most recent fiscal year 2024, Vaxart reported revenues of USD 28.70 mn, with an EBITDA of USD -58.20 mn.Vaxart plans to expand its product offerings with new oral vaccines that are currently in development, targeting launch by 2025. The company aims to enter new geographical markets in North America and Europe by this date as well. The recent funding will be utilized to accelerate these efforts, particularly focusing on enhancing their research capabilities and commercializing their vaccine technologies.

## Funding rounds

- Series C, Aug 5, 2013, $20M — Care Capital
- Series B, Mar 3, 2010, $13M — Care Capital
- Series B, Jan 14, 2010, $3.5M — Quantum Technology Partners, Life Science Angels, Inc.
- Series A, Nov 15, 2007, $3.3M — Bay Partners, Sand Hill Capital, Quantum Technology Partners, Life Science Angels, Inc.

## Investors

- Bay Partners (https://capitalatlas.ai/funds/bay-partners) — Series A
- Sand Hill Capital (https://capitalatlas.ai/funds/sand-hill-capital) — Series A
- Quantum Technology Partners (https://capitalatlas.ai/funds/quantum-technology-partners) — Series A, Series B
- Life Science Angels, Inc. — Series A, Series B
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series B, Series C